News Center


Other Event

BOLD Summit on AI in Radiology, NYU Langone Medical Center

April 24, 2019

Dr. Jennifer E Miller speaks to BiOethics, the Law, and Data-sharing:
AI in Radiology at an event co-sponsored by NYU Langone Medical Center and Stanford University.
Artificial intelligence is a paradigm-shifting force across many fields including medical imaging. Radiology is one of the most data-rich medical subspecialties and leading academic and industry groups are already working to leverage this powerful tool to move our field forward. Research and implementation of AI in Radiology move us into unchartered territories, raising new questions with regard to best practices for data handling.
Dr. Jennifer E. Miller will discuss AI in the framework of ethical principles and privacy considerations.
Location: New York, NY


Other Event

The Forum on Bioethics and Pharma 2019

May 2, 2019 8:30am-2:30pm

In partnership with EY and Scientific American, Bioethics International will hosts its 10th annual Forum on what it means to be a trustworthy, patient-centered & ethical pharma and healthcare innovation company. 

Location: New York, NY


All Events


New York Times interviews our founder, Jennifer Miller, on FDA's clinical trial transparency pilot

The New York Times interviewed our founder, Jennifer Miller, on FDA Commissioner Dr. Scott Gottlieb's clinical trial transparency initiatives. She discussed his new pilot, launched last month, which selects 9 recently-approved drugs, whose sponsors (generally pharmaceutical companies) volunteer to participate, to post portions of Clinical Study Reports (CSRs) from their pivotal trials on FDA's website…

February 12, 2018

Big Data Probably Knows More About You Than Your Friends Do

This week we focused on the ethics of Big Data, publishing an article titled, Big Data Probably Knows More About You Than Your Friends Do, in Leaps Mag. The article discusses the promises and perils of big data and concludes with a way to manage your data wealth.  To read the full article click here.

February 7, 2018

All Posts


Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use Programs

Jeremy Puthumana, MS; Jennifer E. Miller, PhD; Jeanie Kim, JD; et al Joseph S. Ross, MD, MHS. JAMA Network Open. 2018;1(2):e180283. doi:10.1001/jamanetworkopen.2018.0283
The Right to Try Act of 2017 allows patients with life-threatening conditions to access investigational medicines outside clinical trials without oversight from the US Food and Drug Administration (FDA). A better understanding of existing expanded access programs can inform the consideration and implementation of both the federal Right to Try Act and state right-to-try laws.

Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies

Miller JE, Wilenzick M, Ritcey N, et al. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open 2017;0:e017917. doi:10.1136/ bmjopen-2017-017917

Cross-sectional descriptive analysis of all clinical trials supporting 2014 Food and Drugs Administration (FDA)-approved new drug applications (NDAs) for novel drugs sponsored by large companies.

All Publications

Press and Media Inquires

Press and media inquiries can be directed to:

Maggie Beller, Russo Partners LLC

Jennifer Miller, Yale School of Medicine